Comprehensive Stock Comparison
Compare Sangamo Therapeutics, Inc. (SGMO) vs CRISPR Therapeutics AG (CRSP) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | SGMO | -67.2% revenue growth vs CRSP's -90.0% |
| Quality / Margins | SGMO | -331.3% net margin vs CRSP's -13.3% |
| Stability / Safety | CRSP | Beta 1.25 vs SGMO's 1.27, lower leverage |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | CRSP | +36.9% vs SGMO's -57.6% |
| Efficiency (ROA) | CRSP | -21.7% ROA vs SGMO's -122.9%, ROIC -27.4% vs -178.8% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Sangamo Therapeutics is a clinical-stage biotechnology company developing genomic medicines using its zinc finger protein platform for gene editing, cell therapy, and gene regulation. It generates revenue primarily through research collaborations and licensing deals with pharmaceutical partners — including milestone payments and royalties — as its pipeline advances through clinical trials. The company's key competitive advantage is its proprietary zinc finger protein technology platform, which offers precise genome editing capabilities that could enable durable treatments for genetic diseases.
CRISPR Therapeutics is a clinical-stage biotechnology company developing transformative gene-editing therapies for serious diseases using its proprietary CRISPR/Cas9 platform. It generates revenue primarily through research collaborations and milestone payments from partners like Vertex Pharmaceuticals — with its lead therapy for sickle cell disease and beta-thalassemia now approved and generating product sales. The company's key advantage is its foundational CRISPR/Cas9 intellectual property and extensive expertise in developing ex vivo gene-edited cell therapies.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
CRSP leads in 4 of 6 categories (Valuation Metrics, Profitability & Efficiency). SGMO leads in 1 (Financial Metrics).
Financial Metrics (TTM)
CRSP and SGMO operate at a comparable scale, with $37M and $33M in trailing revenue. SGMO is the more profitable business, keeping -3.3% of every revenue dollar as net income compared to CRSP's -13.3%.
| Metric | SGMOSangamo Therapeut… | CRSPCRISPR Therapeuti… |
|---|---|---|
| RevenueTrailing 12 months | $33M | $37M |
| EBITDAEarnings before interest/tax | -$101M | -$556M |
| Net IncomeAfter-tax profit | -$109M | -$488M |
| Free Cash FlowCash after capex | -$76M | -$303M |
| Gross MarginGross profit ÷ Revenue | +100.0% | -3.6% |
| Operating MarginEBIT ÷ Revenue | -3.3% | -15.6% |
| Net MarginNet income ÷ Revenue | -3.3% | -13.3% |
| FCF MarginFCF ÷ Revenue | -2.3% | -8.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | -98.8% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -3.5% | -15.8% |
Valuation Metrics
| Metric | SGMOSangamo Therapeut… | CRSPCRISPR Therapeuti… |
|---|---|---|
| Market CapShares × price | $92M | $5.6B |
| Enterprise ValueMkt cap + debt − cash | $81M | $5.5B |
| Trailing P/EPrice ÷ TTM EPS | -0.88x | -9.30x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 1.59x | 1608.41x |
| Price / BookPrice ÷ Book value/share | 3.83x | 2.81x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
CRSP delivers a -25.5% return on equity — every $100 of shareholder capital generates $-25 in annual profit, vs $-17 for SGMO. CRSP carries lower financial leverage with a 0.11x debt-to-equity ratio, signaling a more conservative balance sheet compared to SGMO's 1.34x. On the Piotroski fundamental quality scale (0–9), CRSP scores 2/9 vs SGMO's 1/9, reflecting mixed financial health.
| Metric | SGMOSangamo Therapeut… | CRSPCRISPR Therapeuti… |
|---|---|---|
| ROE (TTM)Return on equity | -17.4% | -25.5% |
| ROA (TTM)Return on assets | -122.9% | -21.7% |
| ROICReturn on invested capital | -178.8% | -27.4% |
| ROCEReturn on capital employed | -119.9% | -31.1% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 2 |
| Debt / EquityFinancial leverage | 1.34x | 0.11x |
| Net DebtTotal debt minus cash | -$11M | -$141M |
| Cash & Equiv.Liquid assets | $42M | $348M |
| Total DebtShort + long-term debt | $31M | $207M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
Total Returns (with DRIP)
A $10,000 investment in CRSP five years ago would be worth $4,617 today (with dividends reinvested), compared to $361 for SGMO. Over the past 12 months, CRSP leads with a +36.9% total return vs SGMO's -57.6%. The 3-year compound annual growth rate (CAGR) favors CRSP at 6.8% vs SGMO's -47.9% — a key indicator of consistent wealth creation.
| Metric | SGMOSangamo Therapeut… | CRSPCRISPR Therapeuti… |
|---|---|---|
| YTD ReturnYear-to-date | -1.8% | +11.8% |
| 1-Year ReturnPast 12 months | -57.6% | +36.9% |
| 3-Year ReturnCumulative with dividends | -85.8% | +21.9% |
| 5-Year ReturnCumulative with dividends | -96.4% | -53.8% |
| 10-Year ReturnCumulative with dividends | -91.8% | +326.8% |
| CAGR (3Y)Annualised 3-year return | -47.9% | +6.8% |
Risk & Volatility
CRSP is the less volatile stock with a 1.25 beta — it tends to amplify market swings less than SGMO's 1.27 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CRSP currently trades 76.6% from its 52-week high vs SGMO's 40.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SGMOSangamo Therapeut… | CRSPCRISPR Therapeuti… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.27x | 1.25x |
| 52-Week HighHighest price in past year | $1.06 | $78.48 |
| 52-Week LowLowest price in past year | $0.35 | $30.04 |
| % of 52W HighCurrent price vs 52-week peak | +40.8% | +76.6% |
| RSI (14)Momentum oscillator 0–100 | 54.1 | 66.2 |
| Avg Volume (50D)Average daily shares traded | 5.3M | 1.4M |
Analyst Outlook
Wall Street rates SGMO as "Hold" and CRSP as "Buy". Consensus price targets imply 1577.1% upside for SGMO (target: $7) vs 8.1% for CRSP (target: $65).
| Metric | SGMOSangamo Therapeut… | CRSPCRISPR Therapeuti… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | $7.25 | $65.00 |
| # AnalystsCovering analysts | 14 | 38 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.3% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| Sangamo Therapeutic… (SGMO) | 100 | 6.71 | -93.3% |
| CRISPR Therapeutics… (CRSP) | 100 | 96.18 | -3.8% |
CRISPR Therapeutics… (CRSP) returned -54% over 5 years vs Sangamo Therapeutic… (SGMO)'s -96%.
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Sangamo Therapeutic… (SGMO) | $19M | $58M | +198.1% |
| CRISPR Therapeutics… (CRSP) | $5M | $4M | -32.0% |
CRISPR Therapeutics AG's revenue grew from $5M (2016) to $4M (2025) — a -4.2% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Sangamo Therapeutic… (SGMO) | -3.7% | -169.4% | -4484.9% |
| CRISPR Therapeutics… (CRSP) | -4.5% | -165.7% | -3587.9% |
CRISPR Therapeutics AG's net margin went from -4% (2016) to -166% (2025).
Chart 4EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Sangamo Therapeutic… (SGMO) | -1.02 | -0.49 | +52.0% |
| CRISPR Therapeutics… (CRSP) | -1.89 | -6.47 | -242.3% |
CRISPR Therapeutics AG's EPS grew from $-1.89 (2016) to $-6.47 (2025).
Chart 5Free Cash Flow — 5 Years
Sangamo Therapeutics, Inc. generated $-67M FCF in 2024 (+74% vs 2021). CRISPR Therapeutics AG generated $-346M FCF in 2025 (-176% vs 2021).
SGMO vs CRSP: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is SGMO or CRSP a better buy right now?
Analysts rate CRISPR Therapeutics AG (CRSP) a "Buy" — based on 38 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SGMO or CRSP?
Over the past 5 years, CRISPR Therapeutics AG (CRSP) delivered a total return of -53.8%, compared to -96.4% for Sangamo Therapeutics, Inc. (SGMO). A $10,000 investment in CRSP five years ago would be worth approximately $5K today (assuming dividends reinvested). Over 10 years, the gap is even starker: CRSP returned +326.8% versus SGMO's -91.8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SGMO or CRSP?
By beta (market sensitivity over 5 years), CRISPR Therapeutics AG (CRSP) is the lower-risk stock at 1.25β versus Sangamo Therapeutics, Inc.'s 1.27β — meaning SGMO is approximately 1% more volatile than CRSP relative to the S&P 500. On balance sheet safety, CRISPR Therapeutics AG (CRSP) carries a lower debt/equity ratio of 11% versus 134% for Sangamo Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — SGMO or CRSP?
Sangamo Therapeutics, Inc. (SGMO) is the more profitable company, earning -169.4% net margin versus -165.7% for CRISPR Therapeutics AG — meaning it keeps -169.4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SGMO leads at -179.9% versus -189.3% for CRSP. At the gross margin level — before operating expenses — SGMO leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — SGMO or CRSP?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is SGMO or CRSP better for a retirement portfolio?
For long-horizon retirement investors, CRISPR Therapeutics AG (CRSP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.25), +326.8% 10Y return). Both have compounded well over 10 years (CRSP: +326.8%, SGMO: -91.8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between SGMO and CRSP?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.